Portal de recerca
Estudio de fase I/Ib de escalado de la dosis y ampliación de cohortes con OMX-0407, un inhibidor de la cinasa inducible por sal, en pacientes con tumores sólidos irresecables tratados previamente.
Dades bàsiques
- Protocol:
- OMX-0407-101
- EURDRACT:
- NCT:
- Centre:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Any inici:
- 2024
- Any de finalització:
Documents
- No hi ha documents
Grups d'Investigació
Resultats de l'Assaig Clínic
[Translated article] Knowledge of biological therapy in patients with immune-mediated diseases. BIOINFO study.
Segui-Solanes, Carlos; (...); Borras-Blasco, Joaquin
Article. 10.1016/j.farma.2024.08.002. 2024
[Translated article] New challenges in advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2024.05.001. 2024
[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.
Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.12.007. 2025
A Case of Localised Immediate Hypersensitivity Reaction to Bimekizumab.
Lasheras-Perez, Miguel Antonio; (...); Ibanez-Echevarria, Ethel
Article. 10.1111/cod.14774. 2025
Alveolar capillary dysplasia with misalignment of the pulmonary veins: A surgical lung biopsy and autopsy in a full-term newborn.
Rodríguez García C; (...); Mancheño Franch N
Article. 10.1016/j.patol.2024.06.005. 2024
Cost-effectiveness and cost-utility analysis of haemate-P versus other von willebrand disease treatments in Spain.
Megias-Vericat, Juan E; (...); Yan, Songkai
Article. 10.1080/13696998.2025.2474886. 2025
Chronological and Biological Age as a Response Factor to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
Suay, G.; (...); Juan-Vidal, O.
Meeting Abstract. 2024
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.
Ahn, Myung-Ju; (...); Sands, Jacob
Article. 10.1200/JCO-24-01544. 2024
Datopotamab Deruxtecan Vs Docetaxel in Patients with Non-Small Cell Lung Cancer: Final Overall Survival from TROPION-Lung01
Sands, J.; (...); Ahn, M-J
Meeting Abstract. 2024
Delusional parasitosis (Ekbom's syndrome).
Mansilla-Polo, M, Martin-Torregrosa, D, Botella-Estrada, R
Article. 10.1016/j.semerg.2024.102423. 2024
Dermatologic Consultations for Patients Hospitalized in Non-Dermatologic Wards: Results of a 384-Patient Cross-Sectional Study From a Tertiary Referral Hospital
Mansilla-Polo, M.; (...); Botella-Estrada, R.
Letter. 10.1016/j.ad.2024.10.030. 2024
Dermatological toxicities of talquetamab, a new bispecific antibody: case series and literature review.
Mansilla-Polo M; (...); Botella-Estrada R
Letter. 10.1111/ddg.15502. 2024
Dermatological toxicities of talquetamab, a new bispecificantibody: case series and literature review
Mansilla-Polo, Miguel; (...); Botella-Estrada, Rafael
Letter. 10.1111/ddg.15502_g. 2024
Development and testing of a mobile app for systematic collection of patient-reported outcomes (PROs) in patients with hemophilia.
Megias-Vericat, J E; (...); Poveda Andres, J L
Letter. 10.1016/j.thromres.2024.109122. 2024
Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer.
Arriola E; (...); Felip E
Article. 10.1007/s40261-024-01379-7. 2024
First-line Nivolumab (N) plus Ipilimumab (I) plus Chemotherapy (C) in Metastatic NSCLC (mNSCLC): CheckMate 9LA 4-Year Clinical Update
Baclin, Firas; (...); Reck, Martin
Meeting Abstract. 2024
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial.
Reck M; (...); Paz-Ares LG
Article. 10.1016/j.ejca.2024.114296. 2024
FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations
Le, X.; (...); Wang, J.
Meeting Abstract. 2024
Guselkumab, Risankizumab, and Tildrakizumab demonstrate parallel effectiveness and safety in psoriasis treatment: a head-to-head comparative study in real clinical practice.
Mansilla-Polo M; (...); Botella-Estrada R
Article. 10.1016/j.abd.2024.04.004. 2024
Health-Related Quality of Life (HRQoL) Outcomes with Adagrasib vs Docetaxel in KRASG12C-Mutated Advanced NSCLC in KRYSTAL-12
Felip, E.; (...); Duruisseaux, M.
Meeting Abstract. https://doi.org/10.1016/j.jtho.2024.09.056. 2024
Histological deep margins in cutaneous squamous cell carcinoma of the scalp and risk of recurrence.
Verdaguer-Faja, Julia; (...); Jaka, Ane
Article. 10.1111/jdv.20250. 2024
Immune checkpoint inhibitors as first-line treatment for brain metastases in stage IV NSCLC patients without driver mutations
Suay, Guillermo; (...); Lahoz, Agustin
Review. 10.1016/j.canlet.2024.217317. 2024
Incidence, risk factors, and outcomes of BK hemorrhagic cystitis in hematopoietic stem cell transplantation from HLA-matched and haploidentical donors with post-transplant cyclophosphamide.
Chorao, Pedro; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2024.12.006. 2024
Interim analysis of the multinational, post-authorization safety study (NISSO) to assess the long-term safety of sonidegib in patients with locally advanced basal cell carcinoma
Gutzmer, Ralf; (...); Hauschild, Axel
Article. 10.1186/s12885-024-13101-z. 2024
Interparietaler Knoten bei einer 49-jährigen Frau
Mansilla-Polo, Miguel; (...); Botella-Estrada, Rafael
Article. 10.1111/ddg.15398_g. 2024
Mental, emotional and social dimensions of quality of life and their relationship with physical and functional status in adults with haemophilia.
Rodríguez MA; (...); Chimeno-Hernández A
Article. 10.1016/j.thromres.2024.109181. 2024
New challenges of advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2023.11.008. 2024
Nodular hidradenoma: Case report and brief literature review.
Mansilla-Polo, Miguel; (...); Botella-Estrada, Rafael
Article. 10.1016/j.patol.2025.100801. 2025
Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small-Cell Lung Cancer: The Phase II BALTIC Study.
Reinmuth, Niels; (...); Bondarenko, Igor
Article. 10.1158/1078-0432.CCR-24-0013. 2024
Oral Ruxolitinib could Increase the Aggressiveness of Cutaneous Squamous Cell Carcinomas: A 6-Patient Series
Lasheras-Perez, M. A.; (...); Botella-Estrada, R.
Letter. 10.1016/j.ad.2023.07.035. 2025
Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.
Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis
Article. 10.3390/ijms26041760. 2025
Plain language summary: tarlatamab for patients with previously treated small cell lung cancer.
Ahn, Myung-Ju; (...); Paz-Ares, Luis
Article. 10.1080/14796694.2024.2402152. 2024
Recalcitrant Hailey-Hailey Disease With Satisfactory Response to Apremilast
Mansilla-Polo, M.; (...); Botella-Estrada, R.
Letter. 10.1016/j.ad.2024.10.025. 2024
Ruxolitinib for foreign body reaction to silicone in a patient with chronic graft-versus-host disease.
Palacios-Diaz, Rodolfo David; (...); Botella-Estrada, Rafael
Letter. 10.1111/ijd.17365. 2024
Ruxolitinib oral puede aumentar la agresividad de los carcinomas escamosos cutáneos: serie de 6 pacientes.
Lasheras-Perez MA; (...); Botella-Estrada R
Article. 10.1016/j.ad.2024.10.003. 2025
Sacituzumab Govitecan vs Docetaxel in Patients with mNSCLC Non-responsive to Last Anti-PD-(L)1containing Regimen: EVOKE-01
Garassino, M. C.; (...); Paz-Ares, L. G.
Meeting Abstract. 2024
Sarcoidosis cutánea tras inyecciones de plasma rico en plaquetas y maquillaje permanente de cejas.
Martín-Torregrosa D; (...); Botella-Estrada R
Article. 10.1016/j.ad.2024.10.043. 2024
SARS-CoV-2 N protein IgG antibody detection employing nanoporous anodized alumina: A rapid and selective alternative for identifying naturally infected individuals in populations vaccinated with spike protein (S)-based vaccines
Esteve-Sanchez, Yoel; (...); Climent, Estela
Article. 10.1016/j.snb.2024.136378. 2024
Skin cancer risk after hematopoietic stem cell transplantation: a systematic review and meta-analysis.
Mansilla-Polo M; (...); Botella-Estrada R
Article. 10.1111/ijd.17371. 2024
Study of Microsatellite Instability by Immunohistochemistry in a Cohort of Patients With Melanoma
Diaz, Rodolfo David Palacios; (...); Estrada, Rafael Botella
Article. 10.1111/cup.14758. 2025
Successful Treatment of Mogamulizumab-Associated Rash With Upadacitinib: Evidence From 2 Cases.
Martin-Torregrosa, Daniel; (...); Botella-Estrada, Rafael
Article. 10.1001/jamadermatol.2024.4582. 2024
Successful Treatment of Stimulator of Interferon Genes-Associated Vasculopathy of Infantile Onset SAVI Syndrome With Anifrolumab.
Mansilla-Polo M; (...); Botella-Estrada R
Article. 10.1001/jamadermatol.2024.2160. 2024
Sustained response to anti-TNF therapy in ASIA syndrome triggered by vaccination and filler.
Martin-Torregrosa, Daniel; (...); Rodriguez-Serna, Mercedes
Letter. 10.1111/ijd.17650. 2025
Tattoo-Associated Common Wart
Mansilla-Polo, M., Llavador-Ros, M., Botella-Estrada, R.
Editorial Material. 10.1016/j.ad.2024.05.001. 2024
Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.
Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis
Article. 10.1136/ejhpharm-2024-004184. 2024
Treatment of palmoplantar psoriasis with oral roflumilast: a case series.
Lasheras-Perez, Miguel Antonio; (...); Botella-Estrada, Rafael
Article. 10.1093/ced/llae229. 2024
Use of an electrospun bioveil is safe and does not decrease skin graft take on burn wounds: A randomised, controlled clinical trial.
Perez-Del-Caz, Maria Dolores; (...); Perez-Plaza, Aranzazu
Article. 10.1016/j.burns.2025.107427. 2025